Press "Enter" to skip to content

New patent expiration for Gilead Sciences drug BIKTARVY

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug BIKTARVY

Annual Drug Patent Expirations for BIKTARVY
Annual Drug Patent Expirations for BIKTARVY

Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug.

BIKTARVY drug price trends.

Drug patent litigation for BIKTARVY.

This drug has four hundred and forty-five patent family members in sixty-four countries.

The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. One supplier is listed for this compound. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug BIKTARVY
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions